FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
27/06/2025
Voltar para busca
Dado oficial do USPTO
CELLIXIR
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
48
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
12/03/2021
Data de registro
24/12/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
24/12/2024
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
FR
Examinador
COUGHLAN, REBECCA D.
Unidade examinadora
M40
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
CELLECTIS
Representantes
Mary Margaret L. O'Donnell Blue Filament Law PLLC
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals and biochemical products for industrial and scientific use and not for medical or veterinary usefor transferring biological molecules into living cells and for integrating foreign nucleic acids into the genome of living cells; chemical and biochemical soluble substances and solutions for industrial use and not for medical or veterinary purposesfor the transfer of chemical or biological molecules into living cells and the integration of foreign nucleic acids into the genome of living cells; biological preparations for laboratory useother than for medical and veterinary use; diagnostic preparationsother than for medical and veterinary use; peptide substratesprotein arrays and nucleic acids or complexes of these moleculesribo-nucleo and desoxyribo-nucleo complexes for clinical or medical laboratory usefor identifying genetic expression and protein location and integration of foreign nucleic acids into the genome of living cells; chemical and biochemical preparations for industrial and scientific use; chemical and biochemical soluble substances and solutions for industrial use and not for medical or veterinary purposesfor cellular and gene engineering and analysis in laboratories; Chemicalsstandard solutions and buffers used in analytical chemistry for transferring chemical and biological molecules into living cellsintegration of foreign nucleic acids into the genome of living cells and transient production of proteins or nucleic acids; aqueous chemical and biochemical solutions containing nutrients for cultivating living cells for use in electroporation; biological cell and tissue cultures for laboratory use other than for medical and veterinary use; diagnostic reagents other than for medical and veterinary use; peptide substratesprotein array and nucleic acids or complexes of these moleculesribo-nucleo and desoxyribo-nucleo complexesnucleo-proteo complexes for clinical or medical laboratory usein particular for detecting and monitoringfor integrating foreign nucleic acids into the genome of living cells and transient production of proteins; transfection reagents in the nature of chemical and biochemical reagentsused for transient production of proteinsother than for medical and veterinary use
Classe 5
Pharmaceutical and veterinary preparationscellstissuesgrafts engineering reagent for medical or veterinary purposes; diagnostic preparations for medical and veterinary use; living cells and cultures of microorganisms as well as protein arrayssynthetic peptides for the treatment of bloodgeneticimmune disorders and cancer and nucleic acid sequences and complexes of these moleculesribo-nucleo and desoxyribo-nucleo complexesnucleo-proteo complexes for medical and veterinary use; living cells and cultures of microorganisms as well as proteins arrayssynthetic peptides and nucleic acids sequences and complexes of these moleculesribo-nucleo and desoxyribo-nucleo complexesnucleo-proteo complexes for medical and clinical use for the treatment of genetic defects in gene therapyviral and infectious diseasescardiovascular diseases and cancer; diagnostic preparations for medical and veterinary usein particular for the diagnosis and analysis of genetic defectsviral and infectious diseasescardiovascular diseases and cancer; living cellscultures of microorganismsproteins arrayssynthetic peptides and nucleic acids sequences and complexes of these moleculesribo-nucleo and desoxyribo-nucleo complexesnucleo-proteo complexes for medical and veterinary usein particular for medical and clinical use for the treatment of genetic defects in gene therapyviral and infectious diseasescardiovascular diseases and cancer
Publicações
Histórico de despachos e eventos da marca no USPTO.
48 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/06/2025
FIMP
FINAL DISPOSITION PROCESSED
09/06/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/03/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
24/12/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
24/12/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/11/2024
PUBO
PUBLISHED FOR OPPOSITION
05/11/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
16/10/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
30/09/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
30/09/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
30/09/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
30/09/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
30/09/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/09/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/09/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
09/09/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
04/04/2024
GNFR
FINAL REFUSAL E-MAILED
04/04/2024
CNFR
FINAL REFUSAL WRITTEN
04/04/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
14/02/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
18/11/2023
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
10/08/2023
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
26/01/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
27/12/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/12/2022
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
07/12/2022
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
12/06/2022
GNSL
LETTER OF SUSPENSION E-MAILED
12/06/2022
CNSL
SUSPENSION LETTER WRITTEN
12/06/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/04/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/04/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
25/04/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
25/04/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
25/04/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
25/04/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
25/04/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
25/04/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
25/04/2022
RFNT
REFUSAL PROCESSED BY IB
23/11/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
29/10/2021
RFRR
REFUSAL PROCESSED BY MPU
29/10/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
28/10/2021
CNRT
NON-FINAL ACTION WRITTEN
27/10/2021
DOCK
ASSIGNED TO EXAMINER
12/10/2021
MAFR
APPLICATION FILING RECEIPT MAILED
10/07/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/07/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/07/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CELLIXIR ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.